Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)

About This Trial

This study is testing whether adding a hormone therapy medication to targeted treatments, such as focused radiation or surgery, helps delay prostate cancer growth better than targeted treatment alone.
It is designed for men whose cancer has returned after past radiation and has spread to only a few new spots—five or fewer.
To qualify, your cancer must still respond to hormone treatments, and you must not have received chemotherapy for prostate cancer or hormone therapy within the last two years.
If you participate, you will receive targeted treatment for your cancer spots and will attend clinic checkups every three months for up to three years to closely monitor your progress.

The goal of this study is to determine whether the addition of Androgen Deprivation Therapy (ADT) utilizing the study drug ELIGARD® to Recurrence- Directed Therapy (RDT) improves progression-free survival (PFS) compared to RDT alone in patients with early radio-recurrent oligo-metastatic castrate / hormone sensitive prostate cancer (romCSPC).
Participants will be assessed at Standard of Care clinic visits every 3 months.
The follow-up period is 36 months.

Age Range: 18 years and older
Gender: Male
Who This Trial is For: This study is testing whether adding a hormone therapy medication to targeted treatments, such as focused radiation or surgery, helps delay prostate cancer growth better than targeted treatment alone.

Full Eligibility Criteria

Inclusion Criteria

Previous biopsy-proven localized prostate adenocarcinoma (without predominant features of sarcomatoid, small cell or neuroendocrine carcinoma) treated with definitive or salvage radiotherapy ≥ 2 years or more before enrollment.
Recurrent Oligo-metastatic CSPC, M0 on conventional imaging (bone scan and CT scan of chest/abdomen/pelvis) with ≤ 5 metastases cumulative on all imaging, including MRI and PSMA-PET. Note: Patients with conventional imaging M1 oligometastatic CSPC, who have no more than 5 metastatic sites in all imaging modalities including MRI and PSMA-PET, will be accepted for study enrollment.
All sites of recurrent disease must be amenable to treatment with radiotherapy or surgery in the judgment of the investigator.
Biochemical recurrent prostate cancer with ONE of the following PSA recurrence definitions:
- After definitive radiotherapy (prostate in situ), with PSA ≥ nadir + 2ng/ml;
- After prostatectomy and adjuvant/salvage radiotherapy, with PSA ≥ nadir + 0.2ng/ml.

Exclusion Criteria

Age 3 years.
Intracranial or intrathecal metastasis.
Spinal cord compression, or spinal intramedullary metastasis.
Prior malignancy (except non metastatic, non- melanomatous skin cancer) unless disease free for > 3 years.
Bilateral hip prosthesis, treated earlier with definitive prostate radiotherapy, who have evidence of local disease recurrence within the prostate and no option for salvage treatment with brachytherapy or surgery.
Previous documented hypersensitivity to ELIGARD® or other GnRH agonist analogs of components of such preparations.